Skip to main content

Artificial Intelligence and Cancer Clinical Research: III Risk Prediction Models for Febrile Neutropenia in Patients Receiving Cancer Chemotherapy.

Publication ,  Journal Article
Lyman, GH; Kuderer, NM
Published in: Cancer Invest
August 2024

Duke Scholars

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

August 2024

Volume

42

Issue

7

Start / End Page

539 / 543

Location

England

Related Subject Headings

  • Risk Factors
  • Risk Assessment
  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Febrile Neutropenia
  • Artificial Intelligence
  • Antineoplastic Agents
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H., & Kuderer, N. M. (2024). Artificial Intelligence and Cancer Clinical Research: III Risk Prediction Models for Febrile Neutropenia in Patients Receiving Cancer Chemotherapy. Cancer Invest, 42(7), 539–543. https://doi.org/10.1080/07357907.2024.2370692
Lyman, Gary H., and Nicole M. Kuderer. “Artificial Intelligence and Cancer Clinical Research: III Risk Prediction Models for Febrile Neutropenia in Patients Receiving Cancer Chemotherapy.Cancer Invest 42, no. 7 (August 2024): 539–43. https://doi.org/10.1080/07357907.2024.2370692.
Lyman, Gary H., and Nicole M. Kuderer. “Artificial Intelligence and Cancer Clinical Research: III Risk Prediction Models for Febrile Neutropenia in Patients Receiving Cancer Chemotherapy.Cancer Invest, vol. 42, no. 7, Aug. 2024, pp. 539–43. Pubmed, doi:10.1080/07357907.2024.2370692.

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

August 2024

Volume

42

Issue

7

Start / End Page

539 / 543

Location

England

Related Subject Headings

  • Risk Factors
  • Risk Assessment
  • Oncology & Carcinogenesis
  • Neoplasms
  • Humans
  • Febrile Neutropenia
  • Artificial Intelligence
  • Antineoplastic Agents
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis